Ensysce Biosciences Secures Second Financing to Advance Pain Programs

Additional $2 million tranche supports development of abuse- and overdose-resistant analgesics.

Apr. 7, 2026 at 1:08pm

Got story updates? Submit your updates here. ›

A high-end, photorealistic studio still-life photograph featuring a polished, geometric glass vial filled with a clear liquid, representing Ensysce's novel analgesic formulations. The vial is arranged elegantly on a clean, monochromatic seamless background, using sharp, dramatic studio lighting and deep shadows to symbolize the company's focus on developing advanced, safe pain management solutions.Ensysce Biosciences' innovative analgesic formulations, designed to minimize the risk of abuse and overdose, continue to attract investor confidence and support the company's mission to reinvent pain management.San Diego Today

Ensysce Biosciences, a clinical-stage biotech company pioneering novel solutions for severe pain with built-in abuse and overdose protection, has announced the closing of a second $2 million convertible preferred stock financing under a prior $20 million commitment. The funding will maintain the company's flagship analgesic programs and support general corporate initiatives as it continues to advance transformative treatments for patients in severe pain.

Why it matters

Ensysce's differentiated pain management solutions, leveraging its proprietary TAAP and MPAR platforms, aim to provide safer options that minimize the risk of drug abuse and overdose - a critical need given the ongoing opioid crisis. This additional financing underscores investor confidence in the company's approach and its potential to 'reinvent pain management'.

The details

The current $2 million tranche includes a fixed conversion price of $0.55 per share, with an alternate conversion price based on average common stock prices prior to conversion. The financing also includes 100% warrant coverage with an 18-month term and an additional 100% warrant coverage with a five-year term, each exercisable at the fixed conversion price.

  • Ensysce Biosciences secured the $2 million financing on April 7, 2026.
  • The company had a prior commitment of up to $20 million in funding available over 24 months, starting in November 2025.

The players

Ensysce Biosciences, Inc.

A clinical-stage biotech company pioneering novel solutions for severe pain with built-in abuse and overdose protection.

Dr. Kirkpatrick

The CEO of Ensysce Biosciences.

Got photos? Submit your photos here. ›

What they’re saying

“This financing reflects continued investor confidence in Ensysce's differentiated analgesic programs, which we believe have the potential to reinvent pain management.”

— Dr. Kirkpatrick, CEO of Ensysce Biosciences

What’s next

Ensysce plans to use the additional funding to maintain its flagship analgesic programs and support general corporate initiatives as it continues to advance the development of transformative treatments for patients in severe pain.

The takeaway

Ensysce's ability to secure this second tranche of financing underscores investor confidence in the company's innovative approach to pain management, which aims to provide safer, abuse- and overdose-resistant treatment options for patients suffering from severe pain.